 |
 |
 |
|
A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189, a Nucleotide Polymerase Inhibitor, in Healthy Subjects
|
|
|
Reported by Jules Levin EASL 2011 Berlin Germany March 31-Apr 2
A Barry1,J Patti1, M Matson2, B Boehlecke3, E Wenzel1, H Pentikis4, J Alam1, and G Henson1. 1Inhibitex, Inc.





|
|
|
 |
 |
|
|